Biofrontera establishes subsidiary in the US

Biofrontera AG / Biofrontera establishes subsidiary in the US . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Preparing for scheduled market entry in 2016

Monica Tamborini appointed CEO of Biofrontera's US operations

Leverkusen, 20 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, has formed a wholly-owned US subsidiary, Biofrontera Inc., registered in Wilmington, Delaware. This company is intended to lay the ground for marketing and sales activities upon the expected FDA approval for the products Ameluz® and BF-RhodoLED® in 2016.

Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica has over 20 years' experience managing US companies in the healthcare sector. After earning master's degrees in economics and business administration with summa cum laude from Boston University und Suffolk University, and receiving the "Delta Alpha PI Society Award", Monica worked in various sectors before joining the pharmaceutical industry. Since then, Monica has held various positions as CFO and COO. In addition to her expertise in finance Monica has, as Managing Director of Calix Consulting, in recent years concentrated on the communication with the Food and Drug Administration (FDA) and the development of quality management systems, which are mandatory for pharmaceutical and medical device businesses.

Commenting, CEO of Biofrontera, Prof. Dr. Hermann Lübbert, said: "We are very happy that we will be able to rely on Monica's broad expertise when establishing the infrastructure for the distribution of our products in the US.

"An efficient infrastructure, supported by a perfectly well-attuned quality management system, is the foundation of every pharmaceutical company's success. Monica Tamborini's professional background makes her the perfect choice for the development and management of our US business. Since we are expecting FDA approval for our products by the summer of 2016, it is extremely important to start preparing now for the distribution of our products. Monica will initially conduct further market analyses on which the decision will be based whether the cooperation with another distribution partner will be required."